Aurinia Pharmaceuticals (AUPH) 2600 contracts of January 12 calls trade as share price up 13%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Aurinia Pharmaceuticals (AUPH) PT Raised to $9 at RBC Capital
November 11, 2024 6:20 AM ESTRBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $9.00 (from $8.00) while maintaining a Outperform rating.
The analyst comments "Aurinia's Q3/24 product revenues of $55.5MM (+36% y/y) were ~2% ahead of estimates. Management reiterated its 2024 LUPKYNIS net revenue... More
